Bristol-Myers Squibb Company (BMY) Shares Sold by Capital Advisors Inc. OK

Capital Advisors Inc. OK cut its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 0.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 160,869 shares of the biopharmaceutical company’s stock after selling 53 shares during the period. Capital Advisors Inc. OK’s holdings in Bristol-Myers Squibb were worth $8,964,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Hosking Partners LLP lifted its holdings in Bristol-Myers Squibb by 1.6% in the second quarter. Hosking Partners LLP now owns 191,928 shares of the biopharmaceutical company’s stock worth $10,694,000 after buying an additional 3,094 shares during the period. Sphera Funds Management LTD. lifted its holdings in Bristol-Myers Squibb by 65.3% in the second quarter. Sphera Funds Management LTD. now owns 248,000 shares of the biopharmaceutical company’s stock worth $13,819,000 after buying an additional 98,000 shares during the period. State of Tennessee Treasury Department lifted its holdings in Bristol-Myers Squibb by 5.3% in the second quarter. State of Tennessee Treasury Department now owns 1,673,694 shares of the biopharmaceutical company’s stock worth $93,259,000 after buying an additional 84,059 shares during the period. Commerzbank Aktiengesellschaft FI lifted its holdings in Bristol-Myers Squibb by 19.4% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 549,369 shares of the biopharmaceutical company’s stock worth $30,611,000 after buying an additional 89,383 shares during the period. Finally, Condor Capital Management lifted its holdings in Bristol-Myers Squibb by 2.1% in the second quarter. Condor Capital Management now owns 29,888 shares of the biopharmaceutical company’s stock worth $1,665,000 after buying an additional 604 shares during the period. Institutional investors and hedge funds own 68.97% of the company’s stock.

Shares of Bristol-Myers Squibb Company (BMY) opened at $61.24 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a market cap of $99,511.36, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the firm posted $0.77 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. equities analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

WARNING: This story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://sportsperspectives.com/2017/11/22/bristol-myers-squibb-company-bmy-shares-sold-by-capital-advisors-inc-ok.html.

BMY has been the subject of a number of analyst reports. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price for the company. in a research note on Tuesday, August 22nd. Citigroup Inc. set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. Credit Suisse Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Finally, Cowen and Company set a $65.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $64.93.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply